Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder
- Authors
- Han, Changsu; Lee, Moon-Soo; Pae, Chi-Un; Ko, Young-Hoon; Patkar, Ashwin A.; Jung, In-Kwa
- Issue Date
- 15-Aug-2007
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- bipolar disorder; long-acting injections; maintenance; risperidone
- Citation
- PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.31, no.6, pp 1219 - 1223
- Pages
- 5
- Indexed
- SCIE
SCOPUS
- Journal Title
- PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Volume
- 31
- Number
- 6
- Start Page
- 1219
- End Page
- 1223
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/17793
- DOI
- 10.1016/j.pnpbp.2007.04.017
- ISSN
- 0278-5846
1878-4216
- Abstract
- This study aimed to assess the safety, tolerability, efficacy, and compliance of a risperidone long-acting injection (RLAI) formulation for the maintenance treatment of stabilized bipolar patients. A prospective, open-label trial of RLAI was conducted for 12 months. Stable bipolar patients (n=11) were switched from their existing oral antipsychotic agents to RLAI, and injections were given every 2 weeks. The assessments were performed at baseline and at 6 and 12 months of treatment by using the Young Mania Rating Scale (YMRS), Clinical Global Impressions - Severity of Illness (CGI-S) scale, 17-item Hamilton Rating Scale for Depression (HAM-D), Brief Psychiatric Rating Scale (BPRS), and Extrapyramidal Symptom Rating Scale (ESRS). The satisfaction levels of subjects were evaluated at the end of the study period using a 10-point visual analog scale. Ten patients (90.9%) completed the trial, and no significant changes were seen in the YMRS, HAM-D, and BPRS scores throughout the study. CGI-S and ESRS scores were significantly decreased from the baseline to the post-12-month treatment score. Relapses were not reported by any of the participants. This result indicates that RLAI may be beneficial in the maintenance therapy of stable bipolar patients; however, an adequately powered, randomized, placebo-controlled trial is necessary to draw a definite conclusion about the role of RLAI in the maintenance treatment of bipolar patients. (C) 2007 Elsevier Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Psychiatry > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.